NEW YORK, April 10 /PRNewswire-FirstCall/ -- Intellect Neurosciences, Inc. (OTC Bulletin Board: ILNS), announced today that it has obtained a Notice of Allowance and completed the grant requirements to obtain a European patent relating to the Company's ANTISENILIN(R) antibodies and products being developed by the Company for the treatment of Alzheimer's disease. Grant of the European patent is expected in several weeks. Other patents related to the ANTISENILIN(R) antibodies have been granted in Japan, China and elsewhere. Patent applications are pending in the United States. Intellect Neurosciences is the exclusive assignee of the ANTISENILIN(R) patents, which are based on the invention of Dr. Daniel Chain, the Company's Chairman and CEO.
Dr. Chain commented: "The use of ANTISENILIN(R) monoclonal antibodies that specifically target the toxic forms of beta amyloid is at the forefront of the battle against Alzheimer's disease. In addition to the Company's products in development, our invention has been applied to promising drug candidates in clinical development by major pharmaceutical companies."
"Intellect's ANTISENILIN(R) antibody technology incorporates an
important safety feature ("free-end specificity"), meaning that antibodies
developed using the technology are designed to specifically block the
neurotoxicity of beta amyloid, which accumulates in the brains of
Alzheimer's patients. The blocking of the neurotoxicity is achieved by
promoting clearance of beta amyloid away from sites of damage while
minimizing the potential for adverse effects," explained Professor Donald
Price, Professor of Pathology, Neurology and Neuroscience and Founding
Director of the Alzheimer's Disease Research Center at The Johns Hopkins
School of Medicine and a member of Intellect's Scientific Advisory Board.
Professor Price added: "Dr. Chain's idea of using antibodies in this way to
reduce amyloid toxicity in the brain has gained considerable momentum over
|SOURCE Intellect Neurosciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved